Junshi Presents Emerging Results for Two Cancer Drug Studies
ORR signals dominated Junshi Biosciences’ AACR update: in first‑line metastatic colorectal cancer, JS207 plus XELOX produced a 71.0% objective...
eClinical Tech News
CytoDyn Reveals New Leronlimab Data for mTNBC at AACR
In a retrospective cohort of 28 heavily pretreated metastatic triple-negative breast cancer patients, leronlimab exposure was associated with induction...
FDA Fast Tracks bbot’s Promising KRAS Pancreatic Cancer Drug
In early Phase 1 dose escalation, BBOT’s pan-KRAS inhibitor BBO-11818 produced a confirmed partial response in pancreatic ductal adenocarcinoma...
Orion’s ODM-212 Granted Orphan Drug Status for Mesothelioma
Orion Pharma has secured US FDA Orphan Drug Designation for ODM-212 in mesothelioma, adding regulatory leverage to a first-in-class...
Atsena to Advance Pivotal Trial for X-Linked Retinoschisis
An independent data monitoring review of Parts A and B of Atsena Therapeutics’ LIGHTHOUSE study found ATSN-201 safe and...
Ascentage Pharma Presents Promising Cancer Research at AACR
Across four AACR posters, Ascentage reported preclinical synergy signals spanning hematologic and solid tumors: olverembatinib enhanced chemotherapy activity in...
Xenon Presents Azetukalner Phase 3 Seizure Study Results
Azetukalner cut monthly focal-onset seizure frequency by a median 53.2% at 25 mg and 34.5% at 15 mg over...
New Zoldonrasib Clinical Data for KRAS G12D Lung Cancer
In a Phase 1 dose-expansion cohort of previously treated KRAS G12D non-small cell lung cancersmall cell lung cancer, zoldonrasib...
Remedy Plan Therapeutics Announces AACR 2026 Presentations
Remedy Plan Therapeutics will bring a broad slate of AACR presentations centered on RPT1G, its “hyperbolic” NAMPT inhibitor now...
Bioxodes Shares Pivotal Trial Design for BIOX-101 in ICH
Bioxodes is moving BIOX-101 into an adaptive Phase 2b/3 study in intracerebral hemorrhage with functional outcome (mRS) as the...